Scholar Rock Resubmits BLA for Apitegromab in SMA Treatment
Scholar Rock has announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for apitegromab, an investigational therapy intended for the treatment of children and adults living with spinal muscular atrophy (SMA). This resubmission represents a significant milestone for the company as it continues its efforts to bring what could become the first muscle-targeted therapy for SMA to patients in need.
The updated BLA incorporates important manufacturing and regulatory alignments achieved through ongoing discussions with the FDA. Notably, the resubmission includes the Catalent Indiana LLC facility, which is now part of Novo Nordisk, along with an additional U.S.-based fill-finish facility. These inclusions reflect the company’s proactive approach to strengthening its manufacturing capabilities and ensuring supply chain resilience. The decision to incorporate both facilities into the resubmitted application follows guidance received during a Type C meeting with the FDA held on March 3, 2026, as well as multiple interactions throughout the first quarter of the year.
A key outcome of these discussions was the alignment between Scholar Rock and the FDA regarding the timing of the BLA resubmission. The company proceeded with resubmitting the application prior to the FDA’s reinspection of the Catalent Indiana facility, a decision made in agreement with the agency. This step underscores the collaborative nature of the ongoing regulatory process and reflects confidence in the remediation efforts undertaken at the site.
The background to this resubmission dates back to September 2025, when Scholar Rock received a Complete Response Letter (CRL) from the FDA. The CRL was linked to observations identified during a routine inspection of the Catalent Indiana manufacturing facility. Importantly, these observations were not specific to apitegromab itself, and the FDA did not raise concerns regarding the therapy’s clinical efficacy or safety profile. Since then, Scholar Rock, in collaboration with Catalent Indiana and Novo Nordisk, has worked closely with the FDA to address the निरीक्षण findings and implement corrective measures.
Throughout late 2025 and early 2026, several constructive engagements took place between the company and regulatory authorities. These included an in-person Type A meeting in November 2025 and additional discussions in early 2026, followed by an FDA site visit. During these interactions, the FDA did not request further corrective actions beyond the remediation plan already proposed, providing reassurance regarding the progress made at the facility.
In parallel, Scholar Rock accelerated its efforts to qualify a second fill-finish facility within the United States. This strategic move is aimed at enhancing manufacturing flexibility and supporting anticipated global demand for apitegromab, particularly as the company prepares for potential commercial launches. Following discussions with the FDA, the company received alignment to include this second facility as part of the resubmitted BLA, further strengthening the application.
From a regulatory timeline perspective, Scholar Rock expects the FDA to accept the resubmitted BLA within approximately 30 days. Once accepted, the application will undergo a review period of up to six months. Based on this timeline, the company anticipates a Prescription Drug User Fee Act (PDUFA) action date in late September 2026. This projected timeline places the therapy on a potential path toward approval within the year, assuming a favorable review outcome.
The updates included in the resubmission are described as limited in scope, consisting primarily of a standard safety update. This suggests that the core clinical data supporting apitegromab remains unchanged and continues to form the foundation of the application. The therapy has already demonstrated statistically significant and clinically meaningful improvements in motor function in a pivotal Phase 3 clinical trial involving patients with SMA who were receiving SMN-targeted treatments.
Apitegromab is designed as a fully human monoclonal antibody that targets myostatin, a protein that plays a key role in regulating muscle growth. By selectively binding to the precursor forms of myostatin in skeletal muscle, the therapy inhibits its activation, thereby promoting increased muscle mass and strength. This mechanism of action distinguishes apitegromab from existing SMA treatments, which primarily focus on increasing levels of survival motor neuron (SMN) protein. As such, apitegromab has the potential to complement current therapies by directly addressing muscle function.
The FDA has previously granted several important designations to apitegromab, including Fast Track, Orphan Drug, Priority Review, and Rare Pediatric Disease designations. These recognitions highlight both the unmet medical need in SMA and the potential of the therapy to provide meaningful clinical benefits. In Europe, the European Medicines Agency (EMA) has also granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, reflecting similar enthusiasm for the treatment’s potential.
The regulatory progress in the United States is mirrored by ongoing developments in Europe. The EMA is currently reviewing the Marketing Authorisation Application (MAA) for apitegromab, with a decision anticipated around mid-2026. This parallel review process supports Scholar Rock’s broader strategy of pursuing simultaneous approvals across major global markets.
Beyond regulatory considerations, the company is actively preparing for commercialization. The inclusion of a second fill-finish facility not only addresses immediate regulatory requirements but also positions the company to meet future demand efficiently. By diversifying its manufacturing network, Scholar Rock aims to mitigate risks associated with supply disruptions and ensure consistent product availability upon approval.
Leadership at Scholar Rock has emphasized the importance of this milestone in the context of the company’s mission. The resubmission of the BLA is viewed as a critical step toward delivering a novel therapeutic option to individuals living with SMA, a condition characterized by progressive muscle कमजोरी and significant impact on quality of life. The company has expressed optimism regarding continued collaboration with the FDA and a shared commitment to advancing treatments for the SMA community.
To provide further updates and engage with stakeholders, Scholar Rock has scheduled a conference call and webcast. During this session, management is expected to discuss the resubmission in detail, outline next steps, and address questions from investors and analysts. A replay of the webcast will be made available on the company’s website for an extended period, ensuring accessibility for those unable to attend the live event.
Looking ahead, several key milestones remain on the horizon. These include FDA acceptance of the BLA, completion of the review process, and the anticipated PDUFA decision. Concurrently, progress in Europe and continued readiness for commercial launch will be closely monitored. While uncertainties inherent in the regulatory process remain, the current trajectory suggests a potentially transformative year for Scholar Rock and the SMA treatment landscape.
In summary, the resubmission of the apitegromab BLA marks a pivotal moment in the therapy’s development journey. Supported by strong clinical data, regulatory alignment, and enhanced manufacturing capabilities, the application is now positioned for a new phase of FDA review. If approved, apitegromab could introduce a novel, muscle-targeted approach to treating SMA, offering new hope to patients and families affected by this challenging condition.
About Apitegromab
Apitegromab is an investigational fully human monoclonal antibody inhibiting myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. It is the first muscle-targeted treatment candidate in spinal muscular atrophy (SMA) to demonstrate clinical success in a pivotal Phase 3 clinical trial. Myostatin, a member of the TGFβ superfamily of growth factors, is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species, including humans. Scholar Rock believes that its highly selective targeting of pro- and latent forms of myostatin with apitegromab may lead to a clinically meaningful improvement in motor function in patients with SMA. The U.S. Food and Drug Administration (FDA) has granted Fast Track, Orphan Drug and Rare Pediatric Disease designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, to apitegromab for the treatment of SMA. Apitegromab has not been approved for any use by the FDA or any other regulatory agency.
About Scholar Rock
Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases.
